Asia Deal Watch: Bone Therapeutics Licenses Bone Cell Therapy Tech To Two Asian Firms
Executive Summary
Plus deals involving BioAtla/BeiGene, OliX/Thea, Chugai/Argenx, Shionogi/HanaVax, TaiGen/Luminairie, Novartis/1Yao.com, Sperogenix/Minoryx, Quantum/Orient EuroPharma and AtomWise/GC Pharma.
You may also be interested in...
Pfizer Bets $480m On CStone And Surging China Immuno-Oncology Market
The latest big pharma vote of confidence in both the China market and R&D capabilities comes amid continuing standoffs with the US over a flurry of issues including the coronavirus, national security and trade, but as the pandemic seemingly recedes in China.
Alvotech And DKSH Extend Partnership For Six Biosimilars
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.
Need a specific report? 1000+ reports available
Buy Reports